Physician profile
Mark Tusa
NPI 1033395074
$9,058.65
in general payments reported to CMS, 2019-2025
37 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,424 · 2020: $840 · 2021: $1,022 · 2022: $1,366 · 2023: $1,399 · 2024: $1,401 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,207 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,206.96 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,378.07 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Lilly USA, LLC | $1,041.44 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $1,012.04 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $787.43 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $567.96 | 2019-2025 | Adbry, Anzupgo |
| Amgen INC. | $457.97 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $434.77 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $426.24 | 2019-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $386.50 | 2019-2025 | Ilumya |
| Polymedics Innovations INC. | $326.84 | 2025 | |
| Organogenesis INC. | $266.83 | 2023-2025 | Novachor, Puraply, Simplimax |
| Genentech USA, INC. | $236.51 | 2019-2022 | |
| Genzyme Corporation | $227.15 | 2019-2025 | |
| Smith+Nephew, INC. | $177.53 | 2022-2025 | Stravix Mesh, Grafix Xc, Oasis |
| Pfizer INC. | $165.81 | 2020-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $144.14 | 2022-2024 | Sotyktu |
| Incyte Corporation | $128.87 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $123.42 | 2019-2024 | |
| Dermavant Sciences, INC. | $102.32 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $82.10 | 2020-2025 | Nemluvio |
| Almirall LLC | $75.08 | 2020-2024 | Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.51 | 2019-2024 | Targretin, Duobrii, Siliq |
| Mallinckrodt Hospital Products INC. | $58.75 | 2021-2025 | Acthar |
| Celgene Corporation | $51.42 | 2019 | |
| Arcutis Biotherapeutics, INC. | $42.92 | 2023 | |
| Cipher Pharmaceuticals US LLC | $40.10 | 2025 | Spinosad, Natroba |
| Mallinckrodt Enterprises LLC | $35.87 | 2019 | |
| Organon LLC | $31.49 | 2025 | Vtama, Nexplanon |
| Vyne Pharmaceuticals INC. | $28.21 | 2020-2021 | |
| Hill Dermaceuticals, INC. | $23.65 | 2021 | |
| Botanix Sb INC | $22.36 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2023 | Spevigo |
| Epi Health, LLC | $21.11 | 2019-2020 | |
| Medtronic, INC. | $20.20 | 2025 | Venaseal |
| Biofrontera INC. | $15.56 | 2025 | |
| Kerecis Limited | $14.81 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Dermira, INC. | $12.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tusa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.